Matthew James Pianko, MD | Authors

Racial Disparities in Presentation, Diagnosis, and Treatment of MM

October 12, 2022

Closing out the program, Dr Ajay Nooka comments on the structural and biological disparities of care in multiple myeloma between Black and Caucasian patients, including age of presentation, delay of diagnosis and treatment, access to treatment options, and treatment response.

The GMMG HD7 Trial of Isa-VRd vs VRd in Transplant-Eligible NDMM

September 21, 2022

An expert reviews data from the ongoing GMMG HD7 (German) trial investigating isatuximab in combination with bortezomib, lenalidomide and dexamethasone (Isa-VRd) versus VRd in the treatment of transplant-eligible newly diagnosed multiple myeloma.

Is There a Role for MRD-Response Adapted Therapy in Transplant-Eligible NDMM?

September 14, 2022

Dr Ajay Nooka describes key data from the uniquely-designed MASTER trial investigating daratumumab in combination with carfilzomib, lenalidomide and dexamethasone (Dara-KRd) versus KRd in transplant-eligible newly diagnosed multiple myeloma.